- Home
- CX vs QGEN Comparison
CX vs QGEN Comparison
Compare CX & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CX | QGEN |
|---|---|---|
| Founded | 1906 | 1986 |
| Country | Mexico | Netherlands |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 10.2B |
| IPO Year | 1999 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CX | QGEN |
|---|---|---|
| Price | $11.66 | $45.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $10.95 | ★ $50.07 |
| AVG Volume (30 Days) | ★ 7.3M | 1.2M |
| Earning Date | 02-05-2026 | 02-04-2026 |
| Dividend Yield | 0.75% | ★ 3.31% |
| EPS Growth | 231.88 | ★ 331.20 |
| EPS | 0.09 | ★ 1.84 |
| Revenue | ★ $15,869,840,000.00 | $2,070,781,000.00 |
| Revenue This Year | $2.25 | $7.12 |
| Revenue Next Year | $5.11 | $6.13 |
| P/E Ratio | ★ $12.36 | $24.79 |
| Revenue Growth | N/A | ★ 5.32 |
| 52 Week Low | $4.89 | $37.63 |
| 52 Week High | $11.86 | $51.88 |
Technical Indicators
Market Signals| Indicator | CX | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 67.27 | 46.40 |
| Support Level | $11.16 | $44.51 |
| Resistance Level | $11.86 | $45.52 |
| Average True Range (ATR) | 0.29 | 0.64 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 83.94 | 32.96 |
Price Performance
Historical ComparisonAbout CX Cemex S.A.B. de C.V. Sponsored ADR
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and also provide related services and reliable construction-related services to customers and communities and maintain business relationships in more than 60 countries throughout the world. The company operates in different parts of the world, with operations in Mexico, the United States, the EMEA region and the SCA&C region.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).